<SEC-DOCUMENT>0000950170-25-003859.txt : 20250110
<SEC-HEADER>0000950170-25-003859.hdr.sgml : 20250110
<ACCEPTANCE-DATETIME>20250110090443
ACCESSION NUMBER:		0000950170-25-003859
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250110
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250110
DATE AS OF CHANGE:		20250110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Disc Medicine, Inc.
		CENTRAL INDEX KEY:			0001816736
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				851613057
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39438
		FILM NUMBER:		25520708

	BUSINESS ADDRESS:	
		STREET 1:		321 ARSENAL STREET, SUITE 101
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		(617) 674-9274

	MAIL ADDRESS:	
		STREET 1:		321 ARSENAL STREET, SUITE 101
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Gemini Therapeutics, Inc. /DE
		DATE OF NAME CHANGE:	20210209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FS Development Corp.
		DATE OF NAME CHANGE:	20200702
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>iron-20250110.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-01-10T07:59:48.9592+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iron="http://www.discmedicine.com/20250110" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;line-height: 1;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_6e94d574-21e5-48b5-8d6c-ddc7ac23cef7" name="dei:EntityCentralIndexKey" contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28">0001816736</ix:nonNumeric><ix:nonNumeric id="F_220b858b-548e-488b-b973-128c7258c6c8" name="dei:AmendmentFlag" contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="iron-20250110.xsd"/></ix:references><ix:resources><xbrli:context id="C_4ee02671-b947-4018-8fa7-60a545376c28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001816736</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-10</xbrli:startDate><xbrli:endDate>2025-01-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_843876bd-cdac-48b3-8d37-37fa0f5676a3" contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_0f802a51-4ba1-4d48-84fb-14acd94f7d38" contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">January 10, 2025</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_09297284-7003-400e-9c55-8acd8668489d" contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">DISC MEDICINE, INC.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:18%;box-sizing:content-box;"/>
    <td style="width:41%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b4fbce1c-920d-46d4-921a-417cfe856e74" contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_cec6ba87-b6bf-41aa-97ed-886c5ac46103" contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-39438</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_711d24a2-fc72-46c8-99b5-38329abb85d7" contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">85-1612845</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5ba2a3e6-8287-46d3-b876-9f328a6a30a5" contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">321 Arsenal Street</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_30c3d7ad-418b-421f-ad13-b05bbe75c714" contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 101</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_89eea8c1-d6fb-4c5c-ab6b-3fd7f08ee9fc" contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Watertown</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_5bb8a566-5e00-4fe5-bcee-e19497c687a7" contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_7fec1032-b89d-45e9-ad8b-aa897a4c3f1d" contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">02472</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_fca58a77-ff72-48da-82ea-22d5160e4f17" contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">617</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_3edb45d3-e8cd-4b70-a8ea-ff6b84f09860" contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">674-9274</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d5891e69-0056-449f-8e79-83f3959ac2bf" contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c5709562-c808-4929-9db0-486a148602dd" contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a0b7e98a-3519-4bb5-a78f-11461d3a38d3" contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1d734b04-1c14-4197-8339-00a20dec97f0" contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:45%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Title of each class</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_aebf91d8-6a99-46c1-b394-050ee2614a13" contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_574e83fc-37e5-4887-b331-ffff0dd30602" contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">IRON</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_7eaeb63e-9835-48a3-bc30-f0b9e7ca4a1b" contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_6242a91d-8ee2-475e-9850-f33ac5190314" contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7.01 Regulation FD Disclosure.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 10, 2025, Disc Medicine, Inc. (the "Company") issued a press release outlining the Company&#8217;s recent pipeline and operational progress and strategic priorities for 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is intended to be furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such filing. The Company undertakes no obligation to update, supplement or amend the material attached hereto as Exhibit 99.1.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 8.01 Other Events.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company expects to report a material weakness in its internal control over financial reporting in the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2024. This material weakness is related to a lack of design and maintenance of effective Information Technology General Controls (&#8220;ITGC&#8221;) over certain key financial IT systems. As a result, the related business process controls (IT application controls and IT-dependent manual controls) that are dependent on the ineffective ITGCs, or that use information produced from the systems impacted by the ineffective ITGCs, were also ineffective. To date, the Company has not identified any misstatements in its financial statements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's independent registered public accounting firm has not completed its audit of the Company's internal control over financial reporting and, accordingly, does not express an opinion on or any other assessment of it.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:8.96%;box-sizing:content-box;"/>
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:89.04%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="iron-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press release issued by Disc Medicine, Inc. on January 10, 2025, furnished herewith</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6%;box-sizing:content-box;"/>
    <td style="width:44%;box-sizing:content-box;"/>
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:46%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">DISC MEDICINE, INC.</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 10, 2025</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ John Quisel, J.D., Ph.D.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name: John Quisel, J.D., Ph.D. <br/>Title: Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>iron-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;line-height: 1;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 99.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img57926557_0.jpg" alt="img57926557_0.jpg" style="width:263px;height:41px;"></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">In Q1 2025, the Company will discuss the plans for NDA submission under a potential accelerated approval path for bitopertin in erythropoietic protoporphyria (EPP), following a Type C meeting with FDA on confirmatory study design</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Initial data from an ongoing phase 2 study of DISC-0974 (anti-hemojuvelin antibody) in anemia of myelofibrosis (MF) expected H2 2025 </font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Data from higher doses and multiple dose cohorts of a phase 1b study of DISC-0974 in anemia of chronic kidney disease (CKD) expected H2 2025</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Initiation of phase 2 study of DISC-3405 (anti-TMPRSS6 antibody) in polycythemia vera (PV) planned for H1 2025</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">WATERTOWN, Mass., Jan. 10, 2025 &#x2013; Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today outlined its recent pipeline and operational progress and strategic priorities for 2025.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201c;This past year has been another one of tremendous execution and achievement for Disc. During 2024, we successfully advanced every clinical program in our portfolio, transformed our company into a late-stage development organization, and fortified our balance sheet to position us well for Disc&#x2019;s next chapter,&#x201d; said John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc. &#x201c;Most prominently, we completed and presented positive results from our two phase 2 studies of bitopertin in EPP, which showed that reducing PPIX in the blood results in marked improvements across multiple clinical outcomes in EPP patients. This culminated in a successful end-of-phase 2 meeting with the FDA, which provided a path for potential accelerated approval. We will provide an update this quarter on our NDA plans following discussion with the FDA on the design of APOLLO, our planned confirmatory study.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We&#x2019;re equally excited about the data we presented this year from our iron homeostasis portfolio, DISC-0974 and DISC-3405, as these programs will be important drivers of Disc&#x2019;s future growth. In particular, we were encouraged by the robust results from our phase 1b study of DISC-0974 for anemia of myelofibrosis. These data were recently shared in an oral presentation at the 66th American Society of Hematology Annual Meeting and suggest that DISC-0974 has the potential for best-in-class activity. We&#x2019;ve now begun the phase 2 portion of this study and look forward to presenting the initial findings later this year.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Summary of Key Achievements During 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Positive end-of-phase 2 meeting with FDA providing a path toward potential accelerated approval for bitopertin in EPP</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Presentation of full results from phase 2 AURORA and BEACON studies demonstrating significant reductions in PPIX are associated with substantial improvements in time spent in sunlight, measures of quality of life, and reduction in phototoxic reactions </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Presentation of positive data from the phase 1b study of DISC-0974 (anti-hemojuvelin antibody) for anemia of myelofibrosis (MF), demonstrating robust and broad hematologic activity across patient segments</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Results showed substantial and durable improvements in hemoglobin, reductions in transfusion burden, and improvements in fatigue scores</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Initiated the phase 2 portion of the study after positive discussions with FDA</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Presentation of data from initial cohorts of the ongoing phase 1b study of DISC-0974 in anemia of non-dialysis dependent CKD patients, demonstrating hematologic activity following a single dose</font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img57926557_1.jpg" alt="img57926557_1.jpg" style="width:263px;height:41px;"></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Presentation of positive, first-in-human data from the phase 1 SAD / MAD study of DISC-3405 (anti-TMPRSS6 antibody) in healthy volunteers, demonstrating proof-of-mechanism with substantial, dose-dependent increases in hepcidin and reductions in serum iron supportive of a once-monthly dosing regimen  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:3pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Strengthened balance sheet through an equity offering with gross proceeds of approximately $178 million and a non-dilutive debt facility, which provide cash runway well into 2027, and expanded executive team to support next phase of company&#x2019;s growth</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Key Business Objectives and Milestones for 2025</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Bitopertin: GlyT1 Inhibitor (Heme Synthesis Modulator)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Pursue development and global registration of bitopertin in erythropoietic protoporphyria (EPP), with the potential for accelerated approval in the U.S. using PPIX as surrogate endpoint</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Provide update in Q1 2025 on design of confirmatory APOLLO trial and plans for NDA submission, following Type C meeting with FDA</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Initiate global, confirmatory APOLLO trial by mid-2025</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Obtain protocol assistance and feedback on regulatory path from EMA</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Continue to advance pre-commercialization and launch preparation activities</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">DISC-0974: Anti-hemojuvelin Antibody (Hepcidin Suppression)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Pursue next stage of development of DISC-0974 for the treatment of anemia in myelofibrosis patients and generate additional data supporting activity and dose selection in CKD anemia</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Progress ongoing phase 2 MF anemia trial with initial data expected H2 2025</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Progress ongoing phase 1b CKD anemia trial with multiple-dose data expected H2 2025</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Continue to develop scientific rationale for hepcidin suppression in other anemias</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">DISC-3405: Anti-TMPRSS6 Antibody (Hepcidin Induction)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Initiate phase 2 clinical trial of DISC-3405 in PV and broaden role of iron restriction in other indications</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Plan to initiate phase 2 clinical trial of DISC-3405 in PV in H1 2025</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Continued to develop scientific rationale for therapeutic iron restriction in sickle cell disease and other indications</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Bitopertin, DISC-0974, and DISC-3405 are investigational agents and are not approved for use as therapies in any jurisdiction worldwide.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">About Disc Medicine</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit </font><font style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">www.discmedicine.com</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Disc Cautionary Statement Regarding Forward-Looking Statements</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">This press release contains &#x201c;forward-looking statements&#x201d; within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding Disc&#x2019;s</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img57926557_1.jpg" alt="img57926557_1.jpg" style="width:263px;height:41px;"></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">expectations with respect to the next stages of its development programs for bitopertin, DISC-0974 and DISC-3405, including projected timelines for the initiation and completion of its clinical trials, anticipated timing of release of data, and other clinical activities; the registrational pathway for bitopertin, including the potential for accelerated approval; the potential of its development programs in new indications; and the strength of its financial position and its anticipated cash runway. The use of words such as, but not limited to, &#x201c;believe,&#x201d; &#x201c;expect,&#x201d; &#x201c;estimate,&#x201d; &#x201c;project,&#x201d; &#x201c;intend,&#x201d; &#x201c;future,&#x201d; &#x201c;potential,&#x201d; &#x201c;continue,&#x201d; &#x201c;may,&#x201d; &#x201c;might,&#x201d; &#x201c;plan,&#x201d; &#x201c;will,&#x201d; &#x201c;should,&#x201d; &#x201c;seek,&#x201d; &#x201c;anticipate,&#x201d; or &#x201c;could&#x201d; or the negative of these terms and other similar words or expressions that are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Disc&#x2019;s current beliefs, expectations and assumptions regarding the future of Disc&#x2019;s business, future plans and strategies, clinical results and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Disc may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and investors should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of a number of material risks and uncertainties including but not limited to: the adequacy of Disc&#x2019;s capital to support its future operations and its ability to successfully initiate and complete clinical trials; the nature, strategy and focus of Disc; the difficulty in predicting the time and cost of development of Disc&#x2019;s product candidates; Disc&#x2019;s plans to research, develop and commercialize its current and future product candidates; the timing of initiation of Disc&#x2019;s planned preclinical studies and clinical trials; the timing of the availability of data from Disc&#x2019;s clinical trials; Disc&#x2019;s ability to identify additional product candidates with significant commercial potential and to expand its pipeline in hematological diseases; the timing and anticipated results of Disc&#x2019;s preclinical studies and clinical trials and the risk that the results of Disc&#x2019;s preclinical studies and clinical trials may not be predictive of future results in connection with future studies or clinical trials and may not support further development and marketing approval; and the other risks and uncertainties described in Disc&#x2019;s filings with the Securities and Exchange Commission, including in the &#x201c;Risk Factors&#x201d; section of our Annual Report on Form 10-K for the year ended December 31, 2023, and in subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement speaks only as of the date on which it was made. None of Disc, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Media Contact</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Peg Rusconi</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Deerfield Group</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">peg.rusconi@deerfieldgroup.com</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Investor Relations Contact</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Christina Tartaglia</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Precision AQ </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"><br></font><font style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">christina.tartaglia@precisionaq.com</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img57926557_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img57926557_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "( V8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** .8\>ZY>^'O#?VZP9%F\Y$RZ[A@YSQ^%>7?\ "UO$_P#SUM?^_ KO
M_BS_ ,B4?^OF/^M>%5QUYRC.R9]1D^%HU</S3BF[L[;_ (6MXG_YZVO_ 'X%
M>SZ!>3:AX>TZ]N"#-/;1R.5&!N*@FOF*OI;PE_R)^C?]>47_ * *>'G*3=V9
M9UAJ-*G%TXI:]"77];MO#VC3ZE=9*1C"H.KL>BBO!=9\;:]K5T\LM_-!$3\L
M$#E$4>G'7ZFO1?C&9?[ T\#/E&Z^;TSM./ZUXS4XB;YN4WR7"4O8^VDKM_@=
M!H_C;7]&N5EAU":://S0W#F1&_ GCZC!KWGPYKMOXCT2#4;<;=_RR1DY*..H
M_P ]B*^9J]B^#1E_LC4P<^5YZ[?3=MY_3;1AYOFY1YUA*7L?;)6:_$],HHHK
MM/E HHHH **** "BBB@ HHHH *@N99XT_P!'MO.<],N$4?4\G\@:GHH&G9G-
M7D?C.YR+:;1K)>V/,F8?B0!^E<_>^'?B)-DKXGMC[+F+_P!!2O1:*ATT]VSJ
MIXR5/X8Q^Y,\8O=)^)MB"_VN^N%'>"YW_P#CN<_I6(/'?C'2YS%/?W"2+]Z.
MYA4G\=RYKZ"JIJ&EV&JP&"_M(;F/TD0''T/;\*R=!_9DSNIYK!Z5J46O)'DV
MG?&+4HB%U'3[>X3NT1,;?KD?RKN-%^(OA[62L?VK['.?^65S\F?HW0_GFN6\
M1_"-=KW'A^8ANOV29N#[*Y_K^=>6WEG<Z?=26MW!)!/&<-'(N"*R=2K3?O'H
M0P> QL;T='Y?Y?Y'U."",CD45\\>&O'>L>&V2..7[39@\VTS$@#_ &3_  _R
M]C7M?AKQ7IGBBU,EE(5F09EMY.'3_$>XKHIUHS]3Q\9EE;"^\]8]_P#/L;E%
M%%:GG!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5Y3XW\?:YH/BFXT^QD@$$:H5#Q!CR
MH)YKU:O OBA_R/=Y_P!<XO\ T 5AB).,;H];)J5.KB'&HKJWZHE_X6MXG_YZ
MVO\ WX%;W@SX@:[KGBRRTZ]D@-O-YF\)$ >$9AS]0*\KKK/AK_R4#3/^VO\
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M% _$T#2;=D345P^H?%7PW9NR0-<WC#O#'A<_5B/TK(;XS68;Y=&G*^IF /\
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M?]M?_13UR4_C7J?28S_=JG^%_D?05><_$;P)/K4@U?2D#WBJ%FAS@R@="/\
M: XQW'TY]&KGM?\ &FC^&[R.TU%YEEDC\Q=D>X8R1_0UZ%11<;2/B\%4K4ZR
ME05WV/GR;3+^WG,$UE<1R@X*-$P/Y8KM_!'P[OM0U"&^U>V>VL(F#^7*N&F(
MZ#!Y"^I/X>H[?_A:WAC_ )ZW7_?@U/8_$KP[J-_;V5O)<&:>18T#0D#).!7-
M&E33UE<]S$8['3IN,:3CYZG7T445V'S 445!=WMK86YGO+B*WB'5Y7"C]:!I
M-NR)Z*XC4/BKX;LF9('N+QAQF&/"Y^K$?IFL=OC-9AODT><CU,P']*S=:"ZG
M;#+<7-74'^7YGI]%>>6?Q?T29@MS:7EOG^(*KJ/R.?TKKM)\2:-K@']G:A#,
MV,^7G:X_X"<']*<:D9;,RJX.O15ZD&D:M%%%6<QYS\1O D^MR#5]*0/>(@6:
M'.#*HZ$>X].X_7R&;3+^WG,$UE<1R@X*-$P/Y8KZ#U_QIH_AN\CM-1>999(_
M,79'N&,D?T-97_"UO#'_ #UNO^_!KEJ4Z;E>]F?0X'&8RG2452<H]#B/!'P[
MOM0U"&^U>V>VL(F#^7*N&F(Z#!Y"^I/X>H]MKD+'XE>'=1O[>RMY+@S3R+&@
M:$@9)P*Z^M:48Q7NL\[,:V(JU$Z\>7L@HK$\0^*]+\,?9O[2>5?M&[R_+3=]
MW&?_ $(5B?\ "UO#'_/6Z_[\&J<XIV;.>GA*]2/-"#:]#MJ*XI/BGX9DD5%E
MN<L0!^X-=F[K&C.[!549+,< "FI*6S)JX>K2M[2+5^XZBN,U;XG^'-,=HHII
M;Z5>"+9<J#_O$@'\,UA_\+FL]^/['GV^OG#/Y8J75@NIO#+<5-7C!_E^9Z?1
M7%:7\4?#FHR+%+)-92,<#[2H"Y_W@2!^.*[..1)8UDC=71AE64Y!'L:J,E+9
MF%;#U:+M4BT.HHHJC$**** "BLW5O$&DZ'&'U*^AM\C(5CEF^BCD_E7'7GQ?
MT.%BMM:7EQC^+:J*?S.?TJ)5(QW9TT<'7K*].#:/0Z*\P7XS6>[YM&G"^HF!
M/\JU;#XL>'+I@MP+JS)[RQ[E_-23^E)5H/J:RRS%Q5W!_G^1W5%5K'4;+4[<
M3V-U#<1'^*)PP_2K-:'$TT[,****!!7EWCKXDM:RR:5H4@\U?EFNQSM/=4]_
M?\O6MGXE>*GT'1ULK20K?7@(#*>8T'5O8GH/Q]*\)KEKU6O=B?091EL:B]O5
M5UT7ZCI)))I6EE=GD<Y9F.23ZDTVBKVE:-J.MW?V;3K22XEZD+T4>I)X ^M<
M:39]-*48*[=DBC2JS(X96*LIR"#@@UWT?PA\1/#O:?3T;^XTK9_1<5SFN^$=
M:\.X?4+0B$G FC.Y#^(Z?CBK=.25VC"GC,/5ERPFFR]?>-[W5_"+:-J1:>9)
M4>*X/4J,\-ZGW_.N5HHJ7)RW-:5&%)-05D]0KZ6\)?\ (GZ-_P!>47_H KYI
MKZ6\)?\ (GZ-_P!>47_H KHPOQ,\3/\ ^%#U*/Q"_P"1#U7_ *YK_P"AK7SO
M7T1\0O\ D0]5_P"N:_\ H:U\[TL3\2+R'_=Y>OZ(*^@_AK_R3_2_^VO_ *->
MOGROH/X:_P#)/]+_ .VO_HUZ,-\;]!Y]_NT?\2_)G5UP7C_Q[_PCP_LW32C:
MBZY=SR( >G'=CV'XUW%S.EK:S7$GW(D9V^@&37S!J-_/JFI7%]<MNFGD,C?C
MV'L.E;UZCBK+J>5D^"CB*CG4UC'\617-U/>7#W%S,\TTARTDC$DGZU%17=>$
M_AI=>(M/34;F\%I:R$^6 F]W .">H '7_"N*,93=D?4UJ]+#PYJCLCA:*]@;
MX,V17Y-8N WJ8E(_G6:OP@O;?5[0F\@NK#S5\\[2CA <GCGKTZ]ZMT)KH<D<
MWPDMI?@SJOAGX;&B^'A>3KB\OP)&R.43^%?R.3]?:NVI  H    X ':EKOC%
M15D?'UZTJ]1U);L*Q?$OB>P\+Z?]IO&+2/Q% I^:0^WH/4U>U74[;1M+N-0N
MV(A@0L<=3Z >Y/%?-^O:Y=^(=6FU"\<EG.$3/$:]E'L*SK5>166YW99E_P!:
MGS2^%?CY%[Q)XRU;Q-,?M4QBM<_);1$A!]?[Q]S^E<_12JC.X1%+,QP !DDU
MP-MN[/L:=.%*/+!60E%=18_#OQ1?Q"5-,:)",@SNL9_(G/Z4^[^&_BFTC,AT
MTRJ.ODR*Y_+.3^5/V<M[&/US#WY>=7]4<I74>&?'>K^&W2)9#<V(/-M*V0!_
MLG^'^7M7-S036TS0SQ/%*IPR.I4@^X-,56=@J@LQ.  ,DFDFXNZ-*M*G6ARS
M5T?3&@>(;#Q)IRWEA)D=)(VX>-O1A6K7&?#SPC_PC>E&YNE_XF%VH,@_YYKU
M"?7U]_I79UZ<&W%.6Y\'BHTH5I1I.\0KRSXN>' \,6OVZ?.F(KG'<?PM^!X_
M$>E>IU5U*QBU/3+FQG&8KB)HV]LC&?J*52'/&Q>#Q#P]:-1?/T/ENNL^'WB0
M^'O$<8E<BRNR(IQV']UOP)_(FN9N[:2RO)[688EAD:-QZ$'!J&O-BW%W1]S5
MIPKTW"6S/JZBN9\!:T=<\(VDTCEIX?W$Q/4LO0_B,'\:Z:O4B[JZ/@*M.5*;
MIRW1\R>(_P#D:-6_Z_9O_0S696GXC_Y&C5O^OV;_ -#-9E>7+=GZ!1_AQ]$=
M#X5\3OX7DO[F"+?<S6_E0D_=5BP.X^N,=*QKV^N=1NY+N\G>:>0Y9W.2:KUI
MZ/X?U77IFCTRRDG*_>88"K]6/ IW;7*2X4J<I579-[LS**[:3X5>*$B+B&V=
M@/N+.,_KQ^M<A>V5SIUW):7D#PSQG#1N,$42A*.Z"EB:-5VIR3]#1\.^)=0\
M,Z@+JQE.PD>;"Q^24>A']>U>\Q>+M)D\+CQ T^RTV_,#]X/_ ',?WL\?KTKY
MNJ;[5/\ 8_LGG/\ 9_,\SRL_+NQC./7%73K.&AQXW+:>*DI/1]?-'0^*O&^I
M>)YW1W:"P#9CMD/&.Q;^\?\ (KF**Z71_ 7B+6X%N+>Q,<##*RSL$#?0'DCW
MQBH]Z;[G4O886FEI&)S5%=;J'PV\3:?;M.;);A%Y86[AV'_ >I_ 5R1!!P>#
M2<7'=%TJU.JKTY)^A>TK5[[1+Y+S3[AX95ZX/##T8=Q[5[[X-\5P>*])\\*L
M5W%A;B$'A3V(]C_]:OG2NE\!ZV^A^++27=B"=A!,.VUCC/X'!_"M:-1QE;H<
M&9X&.(I.27O+;_(^B:**Y_QEXC3PSX?FNP5-R_[NW4]W(X/T'7\,=Z[VTE=G
MQU.G*I-0CNRCXS\=6GA:+[/$JW&HNN4ASP@[,_\ AWKQ#6-=U+7KLW.HW3S/
M_"I.%0>BCH*JWEW/?WDUW=2M+/,Q=W;J2:@KSZE5S?D?:X'+Z>%CWEU?^045
MIZ-X?U77YS%IEF\Y7[S# 5?JQX%=C#\'M;>,-+?6,;$?=#.V/J=M3&G*6R-Z
MV,H47:I-)GG=.CD>*19(W9'4Y5E."#[&NFUWX?Z_H$#7$]ND]LG+36[;@OU!
M (^N,5R]2XN+LS6G5IU8\T&FCT_P=\4)H)([#Q!(983A4O#]Y/\ ?_O#WZ^N
M:]=CD2:-9(W5XW 964Y!![@U\IUZU\*?%<DQ/A^\?=M4O;.S<X'5/ZC\:ZJ%
M9WY9'@9MED5%UZ*M;=?J>J53U35+/1M.EOKZ8101CDGJ3V '<GTJY7@GQ&\4
M/KVO/:0R?Z!9L4C /#N.&?\ H/8>YK>K4Y(W/(R_!O%U>7HMRKXL\<ZEXGG>
M/>UOIX/R6R'J/5_[Q_05RU%%>=*3D[L^VI4848*%-6045TNB> _$&O0K<6UH
M(K9ONS3ML5OIW(]P,5KW7PD\1P1%XI+&X('W(Y2"?^^E _6J5.;5TC&>-P\)
M<DIJ_J<IHNN:AH%\MWIUPT3C[R]5<>C#N*L>*=<'B/6WU,0F)I(T#IG(#!0#
MCVXK.O;&ZTV[>UO;>2"=/O(XP:KU-W;E-53IN:K):VW\@KK/AK_R4#3/^VO_
M **>N3KK/AK_ ,E TS_MK_Z*>JI_&O4SQG^[5/\ "_R/H*O%?C%_R-%E_P!>
M2_\ H;U[57BOQB_Y&BR_Z\E_]#>NS$? ?+9+_O:]&>=UL^$O^1PT;_K]B_\
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M_P#13UR==9\-?^2@:9_VU_\ 13UST_C7J>YC/]VJ?X7^1]!5XK\8O^1HLO\
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M>AKQOPAX!O\ Q)*EQ.KVNFY^:9A@R#T0=_KT^O2O<M,TNST?3XK&QA6*",<
M=2>Y)[GWKJPT9+7H>!GE7#R:BM9K^K,\A^,7_(T67_7DO_H;UYW7HGQB_P"1
MHLO^O)?_ $-Z\[KGK?&SV,M_W2'H;/A+_D<-&_Z_8O\ T(5]*U\U>$O^1PT;
M_K]B_P#0A7TK73A?A9XF?_Q8>AY1\:?^8'_VW_\ :=>45ZO\:?\ F!_]M_\
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M7POT/266:Z#:C<+R#.,(#[)T_/-=M151HPCT,JV:XJJK.5EY:?\ !$ "@
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M_7K7T#XJV%VPM=;A.GW0.UI,$QD^_=?QR/>O0ZX[Q=\/=/\ $FZZ@VVFH_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!%<VT%Y;O!<PQS0N,-'(H93]0:X;6?A
M/HFH,\MA)+I\K<[4^>//^Z>1^!HHJ90C+=&]'$UJ#O3E8XK4/A-XBM23:FVO
M$[;)-C?B&P/UK!G\%^);8X?1+T_]<XR__H.:**YYT(K5'M87.,1-\LDG\O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3%%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img57926557_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img57926557_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "( V8# 2(  A$! Q$!_\0
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MVO\ WX%;W@SX@:[KGBRRTZ]D@-O-YF\)$ >$9AS]0*\KKK/AK_R4#3/^VO\
MZ*>N:%2;DE<]_%X+#1H3E&"ND^GD?05>?_$/QW+X?*:9IA7[?(F^24C/DJ>F
M!TW'WZ#ZUZ!7SIX],I\<ZMYV=WG<9_N[1M_3%=5>;C'0^?RC#0KU_P!YJDKV
M,Z7Q#K4\QFDU:^:0G.[[0W^/%=OX)^)-];ZA#I^MW!N+25MBW$G+Q$],GNN>
MN>1Z\8KS:BN*-247=,^JKX.C6@X2BO\ (^KJ*K:<9#IEH9L^:84WYZ[MHS5F
MO3/@6K.P4444""BBB@ HHHH **** //_ (A>/)?#S)IFF;/MTB;Y)6&?)4],
M#^\??I^->1R^(=:GF,TFK7S2$YW?:&_QXK1\>F4^.=6\W.[SAC/]W:-OZ8KG
M*\ZK4E*3/M\OP=*E0BTKMJ[?J>D>"?B3?6^H0Z?K=P;BTE8(MQ(?GB)Z9/<?
M7IZ]J]FKY1KZETTR-I=H9B3*84+D]<[1FNC#S<DTSQL[PM.E*-2"M>]RS111
M72>"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !16
M-K/BK1= &-1OXXY<9$*_,Y_X".1]37'W/QCTI'(MM-NY5]794S_.HE4C'=G5
M1P6(K*].#:/2:*\UM_C)ICL!<:7=QKZQNK_SQ76Z)XPT/Q =EA>J9_\ GA(-
MC_@#U_#-$:D);,=7 XBBKS@TC#^+/_(E'_KYC_K7A5>Z_%G_ )$H_P#7S'_6
MO"JX\3\9]+D?^Z_-A7TMX2_Y$_1O^O*+_P! %?--?2WA+_D3]&_Z\HO_ $ 5
M6%^)F&?_ ,*'J/\ $>A0>(]$GTV=MF_#)(!DHXZ'_/8FO -:\*:UH5RT5Y8R
M[ <+-&I:-_<$?R/-?1&JZG;:/ID^H79800@%RHR>2!T_&N5_X6MX8_YZW7_?
M@UK6A"3U=F>=EF)Q5&+]E#FC^IY!H_A;6=<NEAL[&7!/S2NI5$'J6/\ ^NO?
M?#&@0>&M"ATZ%M[#YY9/[[GJ?IV'L!6#_P +6\,?\];K_OP:ZC2-5M=;TN'4
M;(L;>;=L+K@\,5/'U!HHPA%Z.['F>)Q5:*]I!QC^I>HHHKH/&"BLW5O$&DZ%
M&'U*^BM\C*J3EF^BCD_E7&W?Q@T6)RMK97EQC^(A4!^G)/Z5$JD8[LZ:.#KU
ME>G!M'HE%>6CXSP;N=$D"^HN!G_T&M;3_BUX>NF"7275F3_%)'N7\UR?TJ56
M@^IM/+,7%7<'^?Y'>455L=2LM3@\^QNX;F+^]$X;'UQTJU6IPM.+LPHHHH$%
M%-=UC1G=@JJ,EF. !7)ZI\2O#6F.8Q=O=R#JMJN\?]]'"_K4RDH[LUI4*E5V
MIQ;.NHKS";XS6:D^3H\[CMOF"_R!I]O\9=.9\7.E74:^L<BN?R.*CVU/N=?]
ME8RU^3\O\STRBN:TGQ[X<UAECAU!8IFX$5P/+)/H">#^!KI001D<BM%)/8XZ
ME*I2=III^85@^*/"6G>*;+R[I/+N4!\FY4?,A_J/;^5;U%#2:LQ4ZDZ<E.#L
MT?,>N:'?>'M3DL+^/;(O*L/NR+V93W%5;&_NM,O8KRSF:&XB.Y'7M_B/:OHC
MQ9X8MO%&D-:R[4N$RUO-CE&_P/<5\[7MG<:=>S6=U&8YX7*.I[$5Y]6FZ;TV
M/L\OQT<93:E\2W1[SX(\;0>*;4PS!8=2B7,L0Z./[R^WMVKKJ^6M/O[G2[^&
M]LY6BN(6W(P_SR/:OHOPMXBM_$^B17T6%E'R3Q9_U;CJ/IW'M731J\ZL]SPL
MUR[ZO+VE/X7^!M4445T'C!17'W?Q,\.65Y/:S2W(E@D:-\0DC<IP?Y5#_P +
M6\,?\];K_OP:CVD.YUK XEJZIO[CMJ*Y_0/&>D>);N6VTYYFDC3S&WQ[1C('
M]:N:QXCTG08P^I7L<)(RJ=7;Z*.:?-&U[F+H55/V;B^;MU-2BO-KGXQZ5'(1
M;:;=S+_>=E3/\ZFL/B_HMQ($O+2ZM ?X\"11]<<_I4^VAW.EY9BTK\C/0Z*K
M6.H6FIVBW5C<1W$#='C;(^GL?:K-:'$TT[,**:[K&C.[!549+,< "N2U7XE^
M&]+<QK=/>2CJMJNX?]]$A?R)J924=V:4J%2L[4XMG7T5Y@WQFL@^$T><KZF8
M _EBK]E\7=!N'"74%Y:Y_B9 ZC\CG]*A5H/J=4LLQ<5=P9Z!15/3M5L-7MOM
M&GW<5S%W,;9Q[$=0?K5RM4[G#*+B[-684444""BBH;N\MK&W:XN[B*"%>KR,
M% _$T#2;=D345P^H?%7PW9NR0-<WC#O#'A<_5B/TK(;XS68;Y=&G*^IF /\
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M?]M?_13UR4_C7J?28S_=JG^%_D?05><_$;P)/K4@U?2D#WBJ%FAS@R@="/\
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M2_\ H;U[57BOQB_Y&BR_Z\E_]#>NS$? ?+9+_O:]&>=UL^$O^1PT;_K]B_\
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M_P#13UR==9\-?^2@:9_VU_\ 13UST_C7J>YC/]VJ?X7^1]!5XK\8O^1HLO\
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M>AKQOPAX!O\ Q)*EQ.KVNFY^:9A@R#T0=_KT^O2O<M,TNST?3XK&QA6*",<
M=2>Y)[GWKJPT9+7H>!GE7#R:BM9K^K,\A^,7_(T67_7DO_H;UYW7HGQB_P"1
MHLO^O)?_ $-Z\[KGK?&SV,M_W2'H;/A+_D<-&_Z_8O\ T(5]*U\U>$O^1PT;
M_K]B_P#0A7TK73A?A9XF?_Q8>AY1\:?^8'_VW_\ :=>45ZO\:?\ F!_]M_\
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M7POT/266:Z#:C<+R#.,(#[)T_/-=M151HPCT,JV:XJJK.5EY:?\ !$ "@
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M_7K7T#XJV%VPM=;A.GW0.UI,$QD^_=?QR/>O0ZX[Q=\/=/\ $FZZ@VVFH_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!%<VT%Y;O!<PQS0N,-'(H93]0:X;6?A
M/HFH,\MA)+I\K<[4^>//^Z>1^!HHJ90C+=&]'$UJ#O3E8XK4/A-XBM23:FVO
M$[;)-C?B&P/UK!G\%^);8X?1+T_]<XR__H.:**YYT(K5'M87.,1-\LDG\O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3%%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>iron-20250110.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-01-10T07:59:49.4668+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.discmedicine.com/20250110" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iron="http://www.discmedicine.com/20250110" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.discmedicine.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.discmedicine.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="iron-20250110.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.discmedicine.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10091.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45433315385424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 10, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 10,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">DISC MEDICINE, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001816736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-1612845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">321 Arsenal Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Watertown<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">674-9274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IRON<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" "42"I:^YV1R6P$   W$0  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;(V8;W/B-A#&OXK&[73:F22VS-^DP P!<J5W(3309J:=OA"V $ULRY7DD'S[
MK@S8W)U9\P8LXWW\\VKUK$QO)]6KWG)NR'L<);KO;(U)[UQ7!UL>,WTC4Y[
M+VNI8F9@J#:N3A5G81X41Z[O>6TW9B)Q!KW\W%P->C(SD4CX7!&=Q3%3'_<\
MDKN^0YWCB6>QV1I[PAWT4K;A"V[^3.<*1FZA$HJ8)UK(A"B^[CM#>G?OMVQ
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MP %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ E$@J6I>*NQS     $P(
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M,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04
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MYHOA/UY_ 5!+ 0(4 Q0    ( )1(*EH'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ E$@J6NC$K;3O
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ E$@J6IE<G",0!@  G"<  !,              ( !S0$  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "42"I:^YV1R6P$   W$0
M&               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ E$@J6I^@&_"Q @  X@P   T              ( !L P  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " "42"I:EXJ[',     3 @  "P
M        @ &,#P  7W)E;',O+G)E;'-02P$"% ,4    " "42"I:.JJBYT !
M   \ @  #P              @ %U$   >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ E$@J6B0>FZ*M    ^ $  !H              ( !XA$  'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ E$@J6F60>9(9 0
MSP,  !,              ( !QQ(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2      D "0 ^ @  $10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="iron-20250110.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.discmedicine.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="iron-20250110.htm">iron-20250110.htm</File>
    <File>iron-20250110.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "iron-20250110.htm": {
   "nsprefix": "iron",
   "nsuri": "http://www.discmedicine.com/20250110",
   "dts": {
    "inline": {
     "local": [
      "iron-20250110.htm"
     ]
    },
    "schema": {
     "local": [
      "iron-20250110.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.discmedicine.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_4ee02671-b947-4018-8fa7-60a545376c28",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iron-20250110.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4ee02671-b947-4018-8fa7-60a545376c28",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iron-20250110.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.discmedicine.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.discmedicine.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.discmedicine.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.discmedicine.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.discmedicine.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.discmedicine.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.discmedicine.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.discmedicine.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.discmedicine.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.discmedicine.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.discmedicine.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.discmedicine.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.discmedicine.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.discmedicine.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.discmedicine.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.discmedicine.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.discmedicine.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.discmedicine.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.discmedicine.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.discmedicine.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.discmedicine.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.discmedicine.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.discmedicine.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000950170-25-003859-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-003859-xbrl.zip
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M_HY@*Q@[260<RR'Y&"4LX1&+R44]ZAZ R1OD,([).3;+R;G,978M1:/LM%L
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M<XNV)>6W_N0^KLS_XY]1#F^?J;F/9D<W4I_6#N^$'_H^_Q]02P,$%     @
ME$@J6E\)2HGB%   9)    \   !I<F]N+65X.3E?,2YH=&WM76UWTTBR_GSW
M5_1E[]Z%<VP3)Q F-LO9#(&%G0%"PN[LMWO:4MMN(JDUW5(<SZ^_3U6W9/DM
M(;R&(&8.(7KIUZ>JGZJN+CV>%FGRY$_B\53)&#_%XT(7B7KR[#_=@X->__%]
M_RL>N!^>>#PR\5RX8IZHO]U)I9WH;"!D69C_UFEN;"&S8IC+.-;99"!^RB^&
MB<Y4=ZKT9%H,1']XAVN)]7E51GBX6YA\L--[J+/A'UV=Q>IBT-T;ICJKWNWC
M3FZ<+K3)!E8ELM#G:C@R%UVG_Z#:1L;&RG9Q!94\SJORQR8KZ!$UZ._DQ= W
MV=<VY'MCF>ID/GBG4^7$:S43)R:56?7@R!2%2?%LH2Z*KDST!+53@Z@2>K^J
M)S*)L8,_[_"?X6RJ"]5UN8S4(+>J.[,R]]7-?'=&)HF'C;;UT;9+FX.VS'1<
M3 =C770C/*DR:L.SBZD>Z4+XZ:(2GCR^GW_9_B=JS-W7Z40X&_WM#O[Q\-'!
M[O[#AX_^;Z?W/I_<$3(I-EX/K?)=V=W? T+"!#_HYSQSU/K[  @#Y4MV(\((
M*KLZC]MGSM>^NS)1AU;+9.OT_.^?^_L[P\;$M)WZ;)WZ1(F[7I^/M(O$*Q7K
M"/I,O$")"97JQ(FBUHG#:*K5N4KQ;X=?K'%.O%"I+-#(R5P<0S6.3:*-D%DL
M?E%S\7/I4!*>>C-ZKR)29H[OO=*)<H7!+3$V5NSN[#[\BB-=B?9UP+/SZ>"A
M]2!*I'/0&85*NXEV15<E/)Q<7ZYLK3MB[?)$S@?C1%TL=_I]Z0H]GE>U\1-=
M5TA;#+E[72K<#4;2*5J6U@9BT>:]WM[>WE^N&ID/1>#F<=JNXD/M,ZQHW9%5
M\FQPIE2.AB3#JO,ZXX65Q^"2;M-X7P!#N_6(-Y9>7UE_9^<O*\5^WGYZ//@'
MJ+R!+C"DT5:$O,S$VSX#OR.*J1)/39K+;"YF.DD$&AJ5D!JZ@19G7DI>'QT*
M5XY2[1SH@2C!'ZR0(C=4)&H7,HH )RL+%0N@R9IS7,QE,>77L8 :(*S0F<#_
MRLZ+J36YT:K0D<##N&ML/IVC(^+NL^/C>QV\EB1F!MZ!:M[-<[12I K/X\),
MH]CG:!%:@EZ-M24U8(DUE>!.L7+ 4RT M-(MUKM6$%I!: B"9O#&LI!B;$V*
M!0*@FAA"63[%Y(G= "HS%D<O3Y]V=PX>/1!W0<(U>'-JWI?G-,&"+A!QOR?X
M%Y4"R'@EG:O$C/4(JY5VXNZKY_>$NLBQ&D%*7NRR"(H6J"U0KP+J40W0*4@1
M5&]L7* S:9D4.D\47X(ZG(((.<*># CNCS9!> FF$;1Q!DU\IN,,S D]5_3F
MW:>_'*T#ML5KB]</4ZSD22!X;=:D>P]V'@9-^N[5\<GIZ?ZR%LU-,H] %!BD
MYZ 6XN[QO^\Q)\F 1J(5+_J7(?(6TO@OV:4 P2\!G&U]_.WPW;.3=V]^>]T1
MKZ Y>AWQ3YGU1'^GXY=&!GY_;RB6C,..>)E%/7'W]>'IT>';P<N3-Z_!%R6T
MCX82DPG)S42!<QH #]0P4F5!UZ$</<\=&S!<0 CH))9+C-< 8/,.J".6<Y.3
MSNJP=L4KJ;(1.J'_J/&<X>E$%)#JPINCA$5P7<V_N'(\5I88!"MLAW^;THEI
M9:M"SP8%ZT"_32PA$F5!,AL+C?>MMW=SG;.&XV80>>;JB51;,[%DU](-5Q#E
MGC"+UL9"ZAIF;>_;H^<JO*QZY?YZF!?&_;7C8'AT:>C&/[2 > &(AN^FH(^Y
M=(68*VD%]*D8*45+N"F(#AC@!, $) '(F."F+E14,F ))G+A/&%TD#SUQ%')
M, 54'G3$3 &Y,.*<&Y=),A<R/I=9!$PJ$HU:N#S\9$H:VI2 ?>5W 98M)@VE
MIR1:N%6)F\X* _%,) T,BV9#S(2Q$YD%X?(RAR(PSCJ4,I()M4.X*:P_R(NH
M?-0"O9PI6*Q5A_Q@'0R=R#!I(#4R+Y3M^,OQ4#BI8_%/,X7U6T( $VB;WA%T
MSO&4?SS%$(W%,S]NYTJ\&8]U1%8NFG0,@=,Q-W<<!J^:FE<&LX)!P13B?C+G
MD:2N)XIM8;P-'#ARL,6A[2@<5\#;G%<1U,UB9I;629)CU+5L.,,R1O%3'4TQ
M'&:& HNI+%!87$8TD\?'+_]#SY%6&R7&Q'4]N ADGY&*2<DX#WXTZ?UH-8>L
M9QD:"7U0+M1::[>>8"A&98+^LK%/1+*!' '\=<VX6_5ER6:G=L%NK_I #<&H
MQD15*T_!Y1Z%GOA->3=%>)<,MC*'_:90.!KV>PG*Q +!HTINB\J)4;D3@H.#
M$-1L5+T:L/> QO[P^,VOO[[I>)@'UK'N;O@.E&Q+/-:(AZJ4A55" 32D\=1%
MI!EL(Z#?8X',+HCS0H 99*R#:\G5L)W$%,("12#)S&^HQ(6]17J@IKW0<^Q@
M<ZI2I\ZC>J1$O<LG8@M-85VE<A;J;5P6)=H]L6963'M@0Q ?J @(I;2L?F:*
MNI5%:![4;2Q&<^Z.-2,,];KNN<Q.))G<XL\@74!="*-D5: N&$H'XA5T T3)
M\K+!0^@YE/3#N[\/\3L$OX+*R<2IB;0JN/J&7_\PRS [X'Y>C3#G*2<3Y0JO
M^Q8MG<K@M*PU"'L>\607*&#3%#H%VE<7<](CU7A"&V=FA@<GI=< E>JB>0B,
MCZ?=CPZU *KUC$J?21OSDN0[1PVD G1P*XUU1CNOCI<^N\!.KUJ2OKV0_=BJ
M8\O&U?4Z?5JF:"'CEK:=EO:I&@RKW6-:\@"%YE-3*U_)EW(*[=&PWABWT(,'
MCP[Z!_T'#_L[^WL'CVZ9BV@;8(XKXGL9/206YGF=W_9A4E@8UK)7[#2M;S*!
MM7X.3V6+TQ\+ITV: HU.MO R8:J0>_BODS<GATP'?GYV^/3-Z]ILBU5J,G;,
M$(S)FH U&Q&C8T.-BF:[BJTU\"2000?NPX!F.7#ER!$#)+0OF6MDVF'*A,O)
M%,5OKLPX2J(#09(.I)#9(O%9[9E4HL?*6]5UW>Q;G9H"_UWH"-=E:%(K+JVX
M?**XU/Z-Q8[J@E%O-C NVTN]Q/C@S=3.BJP% X?@CJ=DO.1TK;A_Y?0(+@WA
MU(2EZW/#O[_SHV#_T<Y>\\_^9P*_N:FH/PGK0?#!-=4U02^&U3U*U)KJ)HQ/
M$C/266=E)?">TY)]4J/2QBIX0E=+& .RDQ+Z/S(0O!:P+6 _#+!A.Y;]5UO\
M&ZIR;XS)5;'0X[6SU-4<O>4)+4_X1)ZPH >5KZP1N$)@7 ["^H 0ELQDW1@%
MS8D;Q H$F;=KGOYR5.]=K+*%C>2@&7;H\",$UER-^5Q.5#<SL:JZ?6=I&AIG
M+GCF8FT5+P #C'N99BOP7SZ6L7'NT<,-YS7NK+5Q:E>$+J"*L3.@DR7#Y1LH
MV%_F+C$TNZP6!C*9R;F[%4=,+CUBT=]RQ*+_44<L6L78*L;K&E =,=;6[UQ,
M2PS59H-*G!X>B?OB%?Z^7FS55 ';T[DXA^Y!4Y1=4XX@GF9,GKI415.9:9>N
M^28ZK!F["V6KL\AR7(NO(H_(D;?L?.!;3MDR]?MFKLR9AIPK'[)HLDAUT8YB
MFLRI>+;JU 2XR43KH&CEZ]J;,X55V00B0YOW*Z$D4VO*R91V*-7OI?>7A< M
M1OK$>PFLB92*?40M>9LO-%B# CK_I__H)X$F)'6032 AB8\?B=6H@,46:?+%
MK80\B$BZJ;!EAO74![%PD R&\I&W_-1%CA\4?5/'HQ1*IK39&$3&![EX14 A
MO#[89K%)['>'KPJ-;(K#?F]_'[CX/(LM@?\3MZ168\/:O<>U3K?GW+YQE[YN
M6/7/]0[70/PCF;_KBY<9GT[&_-Y]@05/G,XSBBN!#?3*Q&5"<4KWVEF_B;.^
ME1&6UI7+(9(DS>0XE ES(<_1/%_\B(-U==#;<J#,QFW5$$OXK]YI3Y2N#C&4
M%.5LK9E0W!W('RK,BML/LYM*-&_2J9<?DV8>!UH70E%U?<"6HDH7$:5+T:,^
MO%04MMHWV';:MGD6=LM)V._,,FH!^ZT!6^T(A'6E<PDT1W-8.7'W<QW]:V'V
M \'LS:B0%&Y"1 3U4*2+)O=1Y(\UC6%9CV1T1EH2S,;SU7DX#$"^KF>O6M76
M8NYZF'MJ*!(;%)I.'?E#3!2@W5T_RL>AW++,V"^C<AEH==@+TEMWV&\AM?T>
M+:@/MYOK/<.!.%R--CH,?G$RH(/'^K3,*:*?N%=K/-_(J;_">&;7J#]J2)O-
MS=.&JV=;R+RM3_*RD]=O*=.!N:5XL_I\+UOC*F-36=#&9SB7RSLTU7X&[1_7
M\684$T3)&;!@J#H$DW:F?5VW'V+M8MTNUEL-9W^8?37KSJOGE21Z*X0M7=W,
MU_,E\I*TV&NQUQ\U=',3?=4IZ2XK\Q:#+08_K[$2>(IP$1$-.C,BJJ0?BKE*
M'5+A%@25\S!P#@@/V-9FN='$]9HV"\7Q!)NEBN/98*^\S$)T36NMW,A)O]()
M6Y&>.OV&7W66HKGHP-B_%T=;5":L2=B^X4 JJ .\5%L77B70^?.(58B[_<AH
M%]EVD=U"]!*9T0*KKR]O^/OR)',MZEK474[MX@_B=J2O9<Z9ZC8J=*>C,TK0
MI'R*9L[/R9GAMBKZ#XCX"\"X/6O #8[W^Y@^+N*]&JF$.LNYA/@$N<[. 1<]
MJ7($RDGMJJ3;F2E"3$](G%D2>EP G?8!VY2J[7UIM8L#ZB"E28QFJ3;%U6V(
M%3WDM%9+F32__0C\V//Z,7U<_D[&4A)4H=UUTJ#2AJ@NBK! A22H.IO4:5#Y
MWZM94,E1=GD"U-G4A"2H5V= Y81^I*)&I4ZJM"_UISS(N,E0F?1'8NJ Q62^
M.![C$WLUE\\(3=84A^5\BC"I4[\7'/NTJ8)T&N70B HZAX)*-K6,DZ9AYGV@
MU;C,8DE]I8 8[1\-'SB@(W%4""4\\TD7>9'V3\T[7!$G *%F3RE(%[=<':?+
MY[Q74LCUQ',,:&I8LU-&S9 =,T]XW3_73A?U:9A-P'NXOQ?U-P./T1NKR'C^
M,>!/.3 W^FA(SF:S'N$G#:CL 2^7M>Y+B,777*-N![GYZ>H3&E]U?6+%]E1R
MTEK*IW9:0(1Y5_9$3:1EY?#<Y]SK_FK,&?U>/^,^'6]KJ8B?8F!&5G]0,N+_
M^F[FZF.FQJ<?9NUIE==!=%/JS-5Y<$,ZQ&X2IL;54U,GX*5=E!!1GBJ9T5/A
MN/>QU>=DF)^JJ Q)K'_5%9_%_),.%(<1;]#W#PX>=NBL85+&O$*-0&N(X28Z
MU7XUZ]#&C-_:L91$(Z%DPHL&4:Q9 -128LVOK;/$=@]6>YJ\/4W^53[8]XTU
MB]] ]9X+O\L*L:5+Q-A(,RQ">9AD48+\9CQ/G3YW.0'@)9EW:\5![[[WN[>4
M5(W ZNJ0(+WX@$4@P)3/.QRZH48LNPY=A\]71SJ7H;R@W"IU&7)>=!H^F[J$
M1;SAT*?I;9SQ67#,M1XN.O)AAWF&*\]=-IK0TAD TW K#;GE/D^,/U);%3#6
MF<S(-EAD9F=.R_Z'Q9@T3KQRXF#V0: (\@72<:)H*J3;K,RK)6:$24)K%QG=
MJQL>11NN0]'1:=WU.V'NUV]H0F:\?MWG7-Y04#6>Z[>BX !<OY/*^8:+G,AO
MO8)$9NM7*5OT^E4W-66RH?%.J;/UJXO96=P#=A;-1UG-&UX<)[(ZK>\36$.3
MIZX!:X>)2Z0-\XK7PE+,$N[M,39K:)B]Z<F)];$@B>T4HE<SO_5[WL.E--<.
MHE(8RV(UAEPY8,E2U'EI*0[8^92.G#T;8L26%2Y3"FU7*!GSY_#FWAZ5X0LA
MRZFW04\L20I#<>PZ8DF!L;\-E:6Y_WW!,VCL0L5KZ;Q'X0!OIVX:'P1J?MZ#
M/A52ZXLJ'>5BS,-[ )R/1L1XD;ZWVIWYQTKTTA)?8VH%^ F,'6S;D%&"<DJ2
MOL7/D'BL(%\"R2%DVFG*9N;37)-O$"M9LJUL5&S0P&:V;P8!YLY*7_O=  @:
MWIJ=W>-!3R5E]*_3KT.+8=ZBN0_+G'LEL1TDMYJ"LW5$$\>^W*CP*>O#=ST6
M'VOL>,FJQWT)GF2C)\;YQ.Q>>K>/9@ ".Y:-Y61WT <>$PGZ1-^ +&FQ2C2'
MV)NKB^P1A2\;"*8&GK,,L[)! ]EK1"K;!C=/G?%DK7<A3<+V[EW2$G)^R] ,
MGW@D*],1?3=B7->^57P6"^_Z8C7PP(WIFP(>N"OZ0^84]]',X\!K:% -U6=^
MW&()'7'^"/]"X_,L]5YF@YZH55;BE_Q,\M)5*9-Y^,A*5-:?%AB&[R#1%T\P
M(G-.$>N%O5)>K"-\7:[8%%6]U$TLKQ22TG#%#5>?8!U7D+)P2MIH6GL=USR.
MRA.NH'FY\4%/;J@EM#70+[WT';+U%E!6$'2T'K8JA2\W8=-8+HKF>3Z76.O"
M#"VE-5N9]=6BEF\WYKA>"QN!Y>O=#*EX&IF%%^/5S)2=\?KJ<XGP(-8?E?+I
M*"NGIZSW%)>[R>M9@\/5<KL^WQ\TAC6')-'R9, 3WD\LMM*+(U7#UE.4 )3&
M5W"@4;,0A,^#&)ZH/[EC-[:YJJ"2V7%I>>%=/:6?TC=V?/1_S;JK/ONE>IM2
MB96+K!YYY;7RN0^@@[XB41_<;WA)J*!G%Y2A:<+?\:V/#"^45%"&%:T[H:%_
MCA4$2GWQ::0P)!@R^B!(^.C&B>+.XOIS\K_T=[J_U 82?P/%4[@C%2E6GGM]
M_F[;7K5T<+(H:$(:G;?^PSS07+Y4URSV+5:&[!+^1SYT>4:OT)I7)PGDL]8T
MD9Q:!YQE)AUS"&(A6<VT.DP"69F.:2Q)@CIT-$P[6MAPKTE8SNDF.\4+>::8
M=YA14KFBB 65^#5"0\)A;WX?9?EGM_:!,@ I'ZCI&BN/-[,:/OX R+ NHG#&
MS0SE$]F,5%[X GXOM?6?=DGDK/5^?[/ O\_B^Z;]/"DH8@2"V<[E]Q3$>:PF
MXJ1TN*!O<2^/%,QEK<#1_V%-F=^0GG[=;<Y<37K6S_3?XVH\)C0<WV+#<W7S
MH%43GPM6N_W=A[L'7UKEOPR6-?A0$FR^5O]_XXG]J##/*2@]*+\4[\!PY23Y
MY@=ZOV1OCV&1:3YW=/CVT@B4+Z'R'H_LDYL3]1)5$]\KJHG_>UX-C_R]71,^
M)6C\>N<]?K#=\L?WZ0#8DS\]OC\MTN3)_P-02P$"% ,4    " "42"I:.G(J
M<B$5  #6K@  $0              @ $     :7)O;BTR,#(U,#$Q,"YH=&U0
M2P$"% ,4    " "42"I::^EN[X8(   Q80  $0              @ %0%0
M:7)O;BTR,#(U,#$Q,"YX<V102P$"% ,4    " "42"I:7PE*B>(4  !DD
M#P              @ $%'@  :7)O;BUE>#DY7S$N:'1M4$L%!@     #  ,
*NP   !0S      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>iron-20250110_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="iron-20250110.xsd" xlink:type="simple"/>
    <context id="C_4ee02671-b947-4018-8fa7-60a545376c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816736</identifier>
        </entity>
        <period>
            <startDate>2025-01-10</startDate>
            <endDate>2025-01-10</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28"
      id="F_6e94d574-21e5-48b5-8d6c-ddc7ac23cef7">0001816736</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28"
      id="F_220b858b-548e-488b-b973-128c7258c6c8">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28"
      id="F_843876bd-cdac-48b3-8d37-37fa0f5676a3">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28"
      id="F_0f802a51-4ba1-4d48-84fb-14acd94f7d38">2025-01-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28"
      id="F_09297284-7003-400e-9c55-8acd8668489d">DISC MEDICINE, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28"
      id="F_b4fbce1c-920d-46d4-921a-417cfe856e74">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28"
      id="F_cec6ba87-b6bf-41aa-97ed-886c5ac46103">001-39438</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28"
      id="F_711d24a2-fc72-46c8-99b5-38329abb85d7">85-1612845</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28"
      id="F_5ba2a3e6-8287-46d3-b876-9f328a6a30a5">321 Arsenal Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28"
      id="F_30c3d7ad-418b-421f-ad13-b05bbe75c714">Suite 101</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28"
      id="F_89eea8c1-d6fb-4c5c-ab6b-3fd7f08ee9fc">Watertown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28"
      id="F_5bb8a566-5e00-4fe5-bcee-e19497c687a7">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28"
      id="F_7fec1032-b89d-45e9-ad8b-aa897a4c3f1d">02472</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28"
      id="F_fca58a77-ff72-48da-82ea-22d5160e4f17">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28"
      id="F_3edb45d3-e8cd-4b70-a8ea-ff6b84f09860">674-9274</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28"
      id="F_d5891e69-0056-449f-8e79-83f3959ac2bf">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28"
      id="F_c5709562-c808-4929-9db0-486a148602dd">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28"
      id="F_a0b7e98a-3519-4bb5-a78f-11461d3a38d3">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28"
      id="F_1d734b04-1c14-4197-8339-00a20dec97f0">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28"
      id="F_aebf91d8-6a99-46c1-b394-050ee2614a13">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28"
      id="F_574e83fc-37e5-4887-b331-ffff0dd30602">IRON</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28"
      id="F_7eaeb63e-9835-48a3-bc30-f0b9e7ca4a1b">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_4ee02671-b947-4018-8fa7-60a545376c28"
      id="F_6242a91d-8ee2-475e-9850-f33ac5190314">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
